Last edition
News about "Thetis Pharmaceuticals "
The newly approved funding will support a Phase 1b trial of TP-317 in ulcerative colitis patients to identify safe and efficient dosing.
Thetis Pharmaceuticals | 13/01/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members